跳至主要内容
临床试验/EUCTR2017-004543-20-ES
EUCTR2017-004543-20-ES进行中(未招募)1 期

EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA). - PALABA

Fundació Clínic per a la Recerca Biomèdica0 个研究点目标入组 98 人开始时间: 2018年10月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
98

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients with PR according to Guerne and Weissman modified criteria (18) and with:
  • -Disease evolution > 3 months and < 24 months.
  • -ACPA positivity proven by ELISA test or chemiluminescence (CCP2) and/or Rheumatoid factor positivity (ELISA, nephelometry or chemiluminescence).
  • -Greater than 18 years of age.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 98
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • -Persistent arthritis: (involvement in one or more joints > 1 week).
  • -Criteria of other rheumatic diseases (RA, SLE, etc.).
  • -Evidence of radiographic damage (join erosions).
  • -Absence of ACPA or RF.
  • -Contraindication or intolerance to study drugs (abatacept or hydroxychloroquine).
  • -Steroid treatment one month before study entry.
  • -Previous antitrheumatic therapy with synthetic DMARDS (methotrexate, leflunomide, sulfasalazine, cyclosporine, antimalarials.) or biological DMARDs.
  • -Pregnant women or who want to be pregnant during the study.

研究者

发起方
Fundació Clínic per a la Recerca Biomèdica

相似试验